Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Y mAbs Therapeutics (YMAB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: YMAB (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
10 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $14.7
1 Year Target Price $14.7
| 7 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 1 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 50.41% | Avg. Invested days 31 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 204.28M USD | Price to earnings Ratio - | 1Y Target Price 14.7 |
Price to earnings Ratio - | 1Y Target Price 14.7 | ||
Volume (30-day avg) 10 | Beta 0.51 | 52 Weeks Range 3.55 - 16.11 | Updated Date 06/30/2025 |
52 Weeks Range 3.55 - 16.11 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.64 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -31.85% | Operating Margin (TTM) -26.88% |
Management Effectiveness
Return on Assets (TTM) -12.62% | Return on Equity (TTM) -29.93% |
Valuation
Trailing PE - | Forward PE 119.05 | Enterprise Value 144577030 | Price to Sales(TTM) 2.3 |
Enterprise Value 144577030 | Price to Sales(TTM) 2.3 | ||
Enterprise Value to Revenue 1.63 | Enterprise Value to EBITDA -0.43 | Shares Outstanding 45295800 | Shares Floating 25021043 |
Shares Outstanding 45295800 | Shares Floating 25021043 | ||
Percent Insiders 11.73 | Percent Institutions 70.97 |
Analyst Ratings
Rating 4 | Target Price 14.7 | Buy 1 | Strong Buy 7 |
Buy 1 | Strong Buy 7 | ||
Hold - | Sell 1 | Strong Sell 1 | |
Strong Sell 1 |
Upturn AI SWOT
Y mAbs Therapeutics
Company Overview
History and Background
Y mAbs Therapeutics, Inc. was a biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. Founded with the aim of addressing unmet needs in cancer therapy, it focused on GD2-targeted antibodies. It faced significant challenges, including clinical trial setbacks and financial difficulties, leading to its acquisition.
Core Business Areas
- Oncology Therapeutics: Focused on developing antibody-based therapies for treating cancer, primarily targeting GD2-expressing tumors.
Leadership and Structure
Y mAbs Therapeutics had a typical corporate structure with a CEO, CFO, and a board of directors. Their leadership team was focused on clinical development and commercialization of their lead product.
Top Products and Market Share
Key Offerings
- Danyelza (naxitamab-gqgk): Danyelza was Y mAbs Therapeutics' only FDA-approved product, used for the treatment of high-risk neuroblastoma. Limited market share due to its specific indication and competition from other therapies. Competitors included other neuroblastoma treatments like chemotherapy regimens, surgery, and radiation therapy.
Market Dynamics
Industry Overview
The oncology therapeutics market is highly competitive and rapidly evolving, with increasing demand for targeted therapies and immunotherapies.
Positioning
Y mAbs Therapeutics occupied a niche position within the oncology market, focused on GD2-targeted antibodies, especially for neuroblastoma. Their competitive advantage was Danyelza's approval for this specific indication.
Total Addressable Market (TAM)
The TAM for neuroblastoma treatment is estimated in the hundreds of millions of dollars annually. Y mAbs Therapeutics targeted a portion of this TAM with Danyelza.
Upturn SWOT Analysis
Strengths
- FDA-approved product (Danyelza)
- Targeted therapy approach
- Experienced management team in oncology
Weaknesses
- Limited product pipeline
- Financial instability
- Reliance on a single product
- Clinical trial setbacks in other programs
Opportunities
- Expansion of Danyelza's indications
- Partnerships for pipeline development
- Advancements in antibody technology
Threats
- Competition from established pharmaceutical companies
- Clinical trial failures
- Regulatory hurdles
- Patent expirations
Competitors and Market Share
Key Competitors
- JAZZ
- SRPT
- MRTX
- ARRY
Competitive Landscape
Y mAbs Therapeutics faced intense competition from larger pharmaceutical companies with more resources and broader product portfolios. Its competitive advantage stemmed from Danyelza's unique mechanism of action and approval for high-risk neuroblastoma.
Growth Trajectory and Initiatives
Historical Growth: Growth was limited by reliance on Danyelza and setbacks in other pipeline programs. Initially there was growth, but then it stalled and went into decline.
Future Projections: Future projections were uncertain due to the company's financial difficulties prior to acquisition.
Recent Initiatives: Recent initiatives included attempts to expand Danyelza's label and explore new indications, but these were hampered by financial constraints.
Summary
Y mAbs Therapeutics was a biopharmaceutical company with an FDA-approved product for a niche cancer indication. The company struggled with financial instability due to its limited pipeline and high operating expenses. Its dependence on a single product and clinical trial setbacks ultimately led to its acquisition. However, they filled unmet needs in a specific cancer treatment.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Press Releases
- Analyst Reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share estimates are approximations and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Y mAbs Therapeutics
Exchange NASDAQ | Headquaters Princeton, NJ, United States | ||
IPO Launch date 2018-09-21 | CEO, President & Director Mr. Michael Rossi | ||
Sector Healthcare | Industry Biotechnology | Full time employees 104 | Website https://www.ymabs.com |
Full time employees 104 | Website https://www.ymabs.com | ||
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of radioimmunotherapy and antibody based therapeutic products for the treatment of cancer. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company also develops DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumors; and Omburtamab, an antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma. In addition, it engages in the development of CD38-SADA and GD2-GD3 Vaccine; and offers self-assembly disassembly pretargeted radioimmuno therapy (SADA PRIT) technology platform to deliver the radioactive payload to the tumor. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. It operates in the United States, Western Europe, Eastern Asia, Latin America, Western Asia, and internationally. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in Princeton, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.